Skip to main content

Table 2 Respiratory-related medication costs in the 12 months post-index date

From: Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study

Medication typea

ACO cohort (N = 22,328)

COPD only (N = 69,648)

Asthma only (N = 50,293)

 

Total cost (USD)

Number of patients

Mean cost/person (USD)

Total cost (USD)

Number of patients

Mean cost/person (USD)

Total cost (USD)

Number of patients

Mean cost/person (USD)

Anti-IgE

28,993

< 5b

 

2842

< 5b

 

61,397

6

10,233

ICS

132,777

2482

53

116,536

2710

43

283,766

6136

46

LTRA

329,286

2119

155

81,646

993

82

738,900

5659

131

LABA

16,242

944

17

35,013

2023

17

16,909

1832

9

ICS/LABA

2,224,844

7820

285

1,582,052

7732

205

2,465,128

12,579

196

LAMA

742,647

2125

349

1,497,123

4826

310

110,641

488

227

SABA

276,888

9731

28

461,267

22,227

21

222,497

15,299

15

SAMA

86,336

2974

29

181,629

8179

22

54,971

3900

14

SABA/SAMA (SABD)

319,419

5758

55

653,839

14,720

44

181,868

6228

29

Systemic β2-agonist injection

6

20

0.3

34

62

1

15

48

0.3

Systemic β2-agonist oral

241,131

15,384

16

444,653

41,179

11

194,135

35,419

5

Systemic corticosteroids injection (≤14 days)

223,498

8794

25

480,051

24,662

19

197,142

12,936

15

Systemic corticosteroids injection (>14 days)

43,054

719

60

96,799

1745

55

33,618

619

54

Systemic corticosteroids oral (≤14 days)

18,951

10,480

2

34,385

26,126

1

30,325

23,742

1

Systemic corticosteroids oral (>14 days)

62,043

8620

7

97,912

16,564

6

61,374

13,994

4

Xanthine injection

3469

2611

1

4517

4629

1

2102

2894

1

Xanthine oral

295,758

17,934

16

483,469

49,230

10

217,083

37,405

6

Xanthine unknown

2

6

0.3

0.4

8

0.1

0

5

0.0

  1. Differences between variables were assessed using the chi-squared test (categorical variables) or the student’s t-test (continuous variables). All tests were two-sided and p-values < 0.05 were considered statistically significant
  2. ACO asthma-COPD overlap, COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroid, IgE immunoglobulin E, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, LTRA leukotriene receptor antagonist, SABA short-acting β2-agonist, SABD short-acting bronchodilator, SAMA short-acting muscarinic antagonist, USD US dollars
  3. aCategories were not mutually exclusive
  4. bNumbers <5 could not be retrieved from the Health and Welfare Data Science Center